Davide Melisi
Davide Melisi
Associate professor, University of Verona
Verified email at univr.it
Cited by
Cited by
LY2109761, a novel transforming growth factor β receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis
D Melisi, S Ishiyama, GM Sclabas, JB Fleming, Q Xia, G Tortora, ...
Molecular cancer therapeutics 7 (4), 829-840, 2008
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative …
G Tortora, R Caputo, V Damiano, D Melisi, R Bianco, G Fontanini, ...
Clinical cancer research 9 (4), 1566-1572, 2003
Key cancer cell signal transduction pathways as therapeutic targets
R Bianco, D Melisi, F Ciardiello, G Tortora
European journal of cancer 42 (3), 290-294, 2006
Vascular endothelial growth factor receptor-1 contributes to resistance to anti–epidermal growth factor receptor drugs in human cancer cells
R Bianco, R Rosa, V Damiano, G Daniele, T Gelardi, S Garofalo, V Tarallo, ...
Clinical Cancer Research 14 (16), 5069-5080, 2008
Modulation of pancreatic cancer chemoresistance by inhibition of TAK1
D Melisi, Q Xia, G Paradiso, J Ling, T Moccia, C Carbone, A Budillon, ...
Journal of the National Cancer Institute 103 (15), 1190-1204, 2011
Multigene mutational profiling of cholangiocarcinomas identifies actionable molecular subgroups
M Simbolo, M Fassan, A Ruzzenente, A Mafficini, LD Wood, V Corbo, ...
Oncotarget 5 (9), 2839, 2014
Acute-on-chronic liver failure: Pathogenesis, prognostic factors and management
S Blasco-Algora, J Masegosa-Ataz, ML Gutiérrez-García, S Alonso-López, ...
World journal of gastroenterology 21 (42), 12125, 2015
NF-κB as a target for pancreatic cancer therapy
C Carbone, D Melisi
Expert opinion on therapeutic targets 16 (sup2), S1-S10, 2012
NF-κB as a target for cancer therapy
D Melisi, PJ Chiao
Expert opinion on therapeutic targets 11 (2), 133-144, 2007
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma
V Damiano, D Melisi, C Bianco, D Raben, R Caputo, G Fontanini, ...
Clinical Cancer Research 11 (15), 5639-5644, 2005
Angiogenesis: a target for cancer therapy
G Tortora, D Melisi, F Ciardiello
Current pharmaceutical design 10 (1), 11-26, 2004
Secreted interleukin-1α induces a metastatic phenotype in pancreatic cancer by sustaining a constitutive activation of nuclear factor-κB
D Melisi, J Niu, Z Chang, Q Xia, B Peng, S Ishiyama, DB Evans, PJ Chiao
Molecular Cancer Research 7 (5), 624-633, 2009
Anti-VEGF treatment–resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype
C Carbone, T Moccia, C Zhu, G Paradiso, A Budillon, PJ Chiao, ...
Clinical cancer research 17 (17), 5822-5832, 2011
EMT and treatment resistance in pancreatic cancer
N Gaianigo, D Melisi, C Carbone
Cancers 9 (9), 122, 2017
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and …
D Raben, C Bianco, V Damiano, R Bianco, D Melisi, C Mignogna, ...
Molecular cancer therapeutics 3 (8), 977-983, 2004
Emerging pathways and future targets for the molecular therapy of pancreatic cancer
V Vaccaro, D Melisi, E Bria, F Cuppone, L Ciuffreda, MS Pino, A Gelibter, ...
Expert opinion on therapeutic targets 15 (10), 1183-1196, 2011
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative …
G Tortora, R Caputo, V Damiano, G Fontanini, D Melisi, BM Veneziani, ...
Clinical cancer research 7 (12), 4156-4163, 2001
IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-κB activation
Z Zhuang, HQ Ju, M Aguilar, T Gocho, H Li, T Iida, H Lee, X Fan, H Zhou, ...
Clinical Cancer Research 22 (6), 1432-1444, 2016
Metastatic pancreatic cancer: is there a light at the end of the tunnel?
V Vaccaro, I Sperduti, S Vari, E Bria, D Melisi, C Garufi, C Nuzzo, ...
World Journal of Gastroenterology: WJG 21 (16), 4788, 2015
Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers
R Rosa, D Melisi, V Damiano, R Bianco, S Garofalo, T Gelardi, S Agrawal, ...
Clinical Cancer Research 17 (20), 6531-6541, 2011
The system can't perform the operation now. Try again later.
Articles 1–20